Tarsus Pharmaceuticals

Developing innovative therapies for Demodex blepharitis and eye care

Tarsus Pharmaceuticals is dedicated to developing therapies for a range of diseases in need of better solutions. The company’s lead product TP-03 is a topical ophthalmic that targets an underlying cause of blepharitis and has the potential to be the first-ever drug treatment for this condition. Tarsus’ product pipeline includes additional indications in eye care and other areas of high unmet clinical need.

Year of Investment
Life Sciences
Irvine, California